BioCentury | Sep 21, 2015
Company News

Volution, Celsus Therapeutics deal

...Celsus completed its merger with Volution, with the newco to be named Akari Therapeutics plc (NASDAQ:AKTX...
...newco to be named Akari Therapeutics plc (NASDAQ:AKTX, New York, N.Y.) (see BioCentury, Aug. 24). Volution Immuno Pharmaceuticals S.A....
BioCentury | Aug 24, 2015
Financial News

Celsus Therapeutics proposes private placement

...contingent upon Celsus obtaining shareholder approval of the financing and the company’s planned acquisition of Volution Immuno Pharmaceuticals S.A....
BioCentury | Aug 24, 2015
Finance

Coversin operations

...dosing advantage over Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Coversin is owned by Geneva-based Volution Immuno Pharmaceuticals S.A....
...backers for Volution were about five people who put about $20 million into the company. Volution...
BioCentury | Aug 24, 2015
Company News

Volution, Celsus Therapeutics deal

...Volution in a stock transaction, with the newco to be named Akari Therapeutics. Celsus and Volution...
...quarter and GBS and aHUS in 2016. The deal is expected to close this quarter. Volution Immuno Pharmaceuticals S.A....
BioCentury | Aug 19, 2015
Financial News

Celsus, Volution raising $75 million

...Celsus Therapeutics plc (NASDAQ:CLTX) said that after it reverse-merges with Volution Immuno Pharmaceuticals S.A. (Geneva, Switzerland) it will raise...
...which the combined company will be named Akari Therapeutics plc (NASDAQ:AKTX). The lead product is Volution's...
BioCentury | May 25, 2015
Clinical News

Pradaxa dabigatran etexilate: Phase IV started

...mg Pradaxa twice daily vs. warfarin in about 724 patients. RE-CIRCUIT is part of Boehringer’s RE-VOLUTION...
BioCentury | Sep 1, 2014
Clinical News

Pradaxa dabigatran etexilate: Phase III started

...is conducting the trial with Harvard Clinical Research Institute. RE-DUAL PCI is part of Boehringer’s RE-VOLUTION...
Items per page:
1 - 7 of 7
BioCentury | Sep 21, 2015
Company News

Volution, Celsus Therapeutics deal

...Celsus completed its merger with Volution, with the newco to be named Akari Therapeutics plc (NASDAQ:AKTX...
...newco to be named Akari Therapeutics plc (NASDAQ:AKTX, New York, N.Y.) (see BioCentury, Aug. 24). Volution Immuno Pharmaceuticals S.A....
BioCentury | Aug 24, 2015
Financial News

Celsus Therapeutics proposes private placement

...contingent upon Celsus obtaining shareholder approval of the financing and the company’s planned acquisition of Volution Immuno Pharmaceuticals S.A....
BioCentury | Aug 24, 2015
Finance

Coversin operations

...dosing advantage over Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Coversin is owned by Geneva-based Volution Immuno Pharmaceuticals S.A....
...backers for Volution were about five people who put about $20 million into the company. Volution...
BioCentury | Aug 24, 2015
Company News

Volution, Celsus Therapeutics deal

...Volution in a stock transaction, with the newco to be named Akari Therapeutics. Celsus and Volution...
...quarter and GBS and aHUS in 2016. The deal is expected to close this quarter. Volution Immuno Pharmaceuticals S.A....
BioCentury | Aug 19, 2015
Financial News

Celsus, Volution raising $75 million

...Celsus Therapeutics plc (NASDAQ:CLTX) said that after it reverse-merges with Volution Immuno Pharmaceuticals S.A. (Geneva, Switzerland) it will raise...
...which the combined company will be named Akari Therapeutics plc (NASDAQ:AKTX). The lead product is Volution's...
BioCentury | May 25, 2015
Clinical News

Pradaxa dabigatran etexilate: Phase IV started

...mg Pradaxa twice daily vs. warfarin in about 724 patients. RE-CIRCUIT is part of Boehringer’s RE-VOLUTION...
BioCentury | Sep 1, 2014
Clinical News

Pradaxa dabigatran etexilate: Phase III started

...is conducting the trial with Harvard Clinical Research Institute. RE-DUAL PCI is part of Boehringer’s RE-VOLUTION...
Items per page:
1 - 7 of 7